Investor TVM Life Science Ventures VI LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by TVM Life Science Ventures VI LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2023-03-30 13D/A ACER / Acer Therapeutics Inc 2,672,309 1,697,709
2020-10-23 13D/A ALBO / Albireo Pharma Inc 621,761 0
2018-08-27 13D/A ACER / Acer Therapeutics Inc 2,672,309 2,672,309
2018-08-24 13D/A ACER / Acer Therapeutics Inc 2,397,309 2,672,309
2018-02-16 13D ACER / Acer Therapeutics Inc 2,397,309
2017-08-02 13D/A TARA / Protara Therapeutics, Inc. 1,943,059
2016-11-14 13D ALBO / Albireo Pharma Inc 621,761
2014-11-04 13D TARA / Protara Therapeutics, Inc. 1,943,059